Healthcare / BiotechnologyNasdaqCM
$1.71
-0.04 (-2.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-19.1M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$226M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-27.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-48.3M · FCF $-28.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | $3.1M | $698468.00 |
| Net Income | $-48.3M | $-48.3M | $-27.5M | $-19.0M | $-18.1M | $-14.8M | $-2.8M |
| EBITDA | $-53.3M | $-53.3M | $-28.6M | $-19.9M | $-18.1M | — | — |
| EPS | — | — | -1.16 | -3.16 | -4.28 | -4.86 | — |
| Operating Margin | — | — | — | — | — | -476.2% | -403.5% |
| Net Margin | — | — | — | — | — | -476.9% | -407.7% |
| Balance Sheet | |||||||
| Debt/Equity | — | — | 0.00 | 0.02 | 0.02 | 0.01 | — |
| Current Ratio | 30.14 | 30.14 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-28.2M | $-28.2M | $-19.1M | $-18.1M | $-17.6M | $-14.3M | — |
| Returns | |||||||
| ROE | -27.9% | -27.9% | -29.0% | -173.3% | -85.8% | -38.5% | -29.1% |
| Valuation | |||||||
| P/B | 1.30 | 1.30 | 0.83 | 0.74 | 0.67 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | — | — | 343.9% | — |
| EPS Growth | — | — | 63.3% | 26.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.16 → n/d
Residual
-14.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.